Omeros Corporation’s (OMER) “Buy” Rating Reiterated at WBB Securities
Omeros Corporation (NASDAQ:OMER)‘s stock had its “buy” rating reissued by stock analysts at WBB Securities in a report issued on Monday. They presently have a $75.00 price objective on the biopharmaceutical company’s stock.
Several other research analysts have also recently weighed in on the company. S&P Equity Research lifted their price target on Omeros Corporation from $7.65 to $8.63 in a research report on Monday. Zacks Investment Research cut Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, October 12th. Wedbush reiterated an “outperform” rating and set a $56.00 price target (down from $62.00) on shares of Omeros Corporation in a research report on Thursday, August 11th. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Omeros Corporation in a report on Wednesday, August 10th. Finally, Maxim Group dropped their price objective on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, August 10th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $32.45.
Omeros Corporation (NASDAQ:OMER) traded up 3.54% during mid-day trading on Monday, reaching $7.60. The company had a trading volume of 3,868,671 shares. The stock’s market capitalization is $298.63 million. The stock has a 50 day moving average of $10.60 and a 200 day moving average of $11.73. Omeros Corporation has a 52 week low of $7.26 and a 52 week high of $16.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/omeros-corporations-omer-buy-rating-reiterated-at-wbb-securities.html
Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.18. The company had revenue of $10 million for the quarter, compared to analysts’ expectations of $9.80 million. The firm’s revenue was up 212.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.44) earnings per share. Analysts anticipate that Omeros Corporation will post ($1.55) earnings per share for the current year.
In related news, VP Marcia S. Kelbon sold 16,000 shares of Omeros Corporation stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total transaction of $174,560.00. Following the transaction, the vice president now owns 179,597 shares in the company, valued at $1,959,403.27. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Marcia S. Kelbon sold 15,900 shares of Omeros Corporation stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $11.56, for a total value of $183,804.00. Following the transaction, the vice president now owns 179,497 shares in the company, valued at approximately $2,074,985.32. The disclosure for this sale can be found here. 13.60% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the company. BlackRock Fund Advisors increased its position in shares of Omeros Corporation by 0.7% in the first quarter. BlackRock Fund Advisors now owns 1,471,968 shares of the biopharmaceutical company’s stock worth $22,580,000 after buying an additional 10,605 shares during the last quarter. UBS Group AG increased its position in shares of Omeros Corporation by 0.8% in the first quarter. UBS Group AG now owns 333,744 shares of the biopharmaceutical company’s stock worth $5,120,000 after buying an additional 2,631 shares during the last quarter. Bank of Montreal Can bought a new position in shares of Omeros Corporation during the second quarter worth approximately $17,641,000. Chicago Equity Partners LLC bought a new position in shares of Omeros Corporation during the second quarter worth approximately $961,000. Finally, Bourgeon Capital Management LLC bought a new position in shares of Omeros Corporation during the second quarter worth approximately $158,000. Hedge funds and other institutional investors own 48.04% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.